Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company dedicated to developing and commercializing supportive care therapies for oncology patients. The company's flagship product, PEDMARK (marketed as PEDMARQSI in Europe), is a unique formulation of sodium thiosulfate. It is the first and only FDA- and EMA-approved treatment indicated to reduce the risk of permanent hearing loss (ototoxicity) associated with cisplatin chemotherapy in pediatric patients with localized, non-metastatic solid tumors. Fennec primarily operates in the United States, where it markets PEDMARK directly to hospitals, cancer centers, and pediatric oncologists. Internationally, the company has established an exclusive licensing agreement with Norgine Pharmaceuticals to commercialize the therapy across Europe, the U.K., Australia, and New Zealand. Originally incorporated in 1996 as Adherex Technologies, the company rebranded to Fennec Pharmaceuticals in 2014 to reflect its focused strategic direction.
